Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: The non-randomised ISID study

Christine Verboon, Bianca Van Den Berg, David R. Cornblath, Esmee Venema, Kenneth C. Gorson, Michael P. Lunn, Hester Lingsma, Peter Van Den Bergh, Thomas Harbo, Kathleen Bateman, Yann Pereon, Søren H. Sindrup, Susumu Kusunoki, James Miller, Zhahirul Islam, Hans Peter Hartung, Govindsinh Chavada, Bart C. Jacobs, Richard A.C. Hughes, Pieter A. Van Doorn

Research output: Contribution to journalArticle

Abstract

Objective To compare disease course in patients with Guillain-Barré syndrome (GBS) with a poor prognosis who were treated with one or with two intravenous immunoglobulin (IVIg) courses. Methods From the International GBS Outcome Study, we selected patients whose modified Erasmus GBS Outcome Score at week 1 predicted a poor prognosis. We compared those treated with one IVIg course to those treated with two IVIg courses. The primary endpoint, the GBS disability scale at 4 weeks, was assessed with multivariable ordinal regression. Results Of 237 eligible patients, 199 patients received a single IVIg course. Twenty patients received an α early' second IVIg course (1-2 weeks after start of the first IVIg course) and 18 patients a α late' second IVIg course (2-4 weeks after start of IVIg). At baseline and 1 week, those receiving two IVIg courses were more disabled than those receiving one course. Compared with the one course group, the adjusted OR for a better GBS disability score at 4 weeks was 0.70 (95%CI 0.16 to 3.04) for the early group and 0.66 (95%CI 0.18 to 2.50) for the late group. The secondary endpoints were not in favour of a second IVIg course. Conclusions This observational study did not show better outcomes after a second IVIg course in GBS with poor prognosis. The study was limited by small numbers and baseline imbalances. Lack of improvement was likely an incentive to start a second IVIg course. A prospective randomised trial is needed to evaluate whether a second IVIg course improves outcome in GBS.

Original languageEnglish (US)
Pages (from-to)113-121
Number of pages9
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume91
Issue number2
DOIs
StatePublished - Feb 1 2020

    Fingerprint

Keywords

  • Guillain-Barré syndrome
  • poor prognosis
  • second IVIg course
  • treatment

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Verboon, C., Van Den Berg, B., Cornblath, D. R., Venema, E., Gorson, K. C., Lunn, M. P., Lingsma, H., Van Den Bergh, P., Harbo, T., Bateman, K., Pereon, Y., Sindrup, S. H., Kusunoki, S., Miller, J., Islam, Z., Hartung, H. P., Chavada, G., Jacobs, B. C., Hughes, R. A. C., & Van Doorn, P. A. (2020). Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: The non-randomised ISID study. Journal of Neurology, Neurosurgery and Psychiatry, 91(2), 113-121. https://doi.org/10.1136/jnnp-2019-321496